Ginkgo Bioworks Intrinsic Value Calculator – Barry Canton Profits from Ginkgo Bioworks Holdings, Stock Sale of 37,650 Shares
August 8, 2023
☀️Trending News
Barry Canton recently profited from the sale of 37,650 shares of Ginkgo Bioworks ($NYSE:DNA) Holdings, Inc. stock at Defense World. Ginkgo Bioworks is a leading biotechnology company that specializes in engineering organisms for industrial purposes. Through its groundbreaking research and cutting-edge technology, Ginkgo Bioworks creates living solutions for customers across various industries, including health, consumer goods, food and agriculture, chemicals, and energy. The company’s suite of platform technologies enables its customers to engineer organisms for increased sustainability, affordability, and scalability. The potential return on investment is further increased by Ginkgo Bioworks’ impressive list of partnerships and collaborations with industry-leading companies, such as the Microsoft Azure platform and Bayer Crop Science.
The company also recently announced an exclusive multi-year partnership with Microsoft Azure to develop an automated organism design platform. With such a strong enterprise portfolio and a continuously expanding customer base, Ginkgo Bioworks’ stock is poised to continue increasing in value. Barry Canton’s sale of 37,650 shares of Ginkgo Bioworks stock shows his wisdom and understanding of the biotechnology sector’s potential, and it is likely that he will continue to benefit from his investment in the future. It is no surprise that Ginkgo Bioworks is considered one of the most important companies in the biotechnology sector; one could argue that it is a smart move to invest in Ginkgo Bioworks’ stock before its value rises even further.
Market Price
The stock opened at $2.4 and closed at $2.5, up by 2.9% from its prior closing price of 2.4. Canton’s timing was spot on, as the stock price has continued to rise since the sale of his shares. This is a great example of how savvy investors can capitalize on market trends and make a significant return on their investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 390 | -1.72k | -440.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -322.88 | -50.82 | 95.64 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.42k | 809.62 | 0.83 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 106.6% | – | -426.1% |
| FCF Margin | ROE | ROA |
| -100.3% | -62.1% | -43.0% |
Analysis – Ginkgo Bioworks Intrinsic Value Calculator
At GoodWhale, we have conducted extensive analysis of GINKGO BIOWORKS‘s fundamentals. After careful review, we have calculated the fair value of a GINKGO BIOWORKS share to be around $5.4. This fair value was calculated using our proprietary Valuation Line. Currently, however, GINKGO BIOWORKS stock is being traded at $2.5, making it undervalued by 53.5%. This presents an excellent opportunity for investors to purchase shares in the company and benefit from potential gains when the stock returns to its fair value. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Ginkgo Bioworks Holdings, Inc. (GINKGO) recently saw one of its executives, Barry Canton, liquidating part of his stock holdings in the company. This signals to investors that there may be a lack of confidence in the near future prospects of GINKGO’s stock. Analysts suggest that investors should look at the fundamentals of the company to determine if they want to invest in GINKGO over the long term. Factors to consider include GINKGO’s financials, market positioning, and competitive landscape.
Investors should also pay attention to the company’s progress with its various projects, as well as the company’s overall strategies and focus. By carefully analyzing the available information, investors can determine if GINKGO is a suitable long-term investment opportunity.
Related Posts
Recent Posts
